{"schema_version":"secwatch.filing_event.v1","accession":"0001326190-25-000024","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2025-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.308664+00:00","generated_at":"2026-05-24T20:31:30.649636+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Altimmune to pursue two new indications for pemvidutide: AUD and ALD, Phase 2 trials starting Q2/Q3 2025","bullets":["Phase 2 AUD trial for pemvidutide targeting moderate to severe AUD; ~100 subjects, 24 weeks, endpoints include heavy drinking days.","Phase 2 ALD trial for pemvidutide targeting obesity and ALD; ~100 subjects, 48 weeks, endpoints include liver stiffness and biomarkers.","Both Phase 2 trials are randomized, double-blind, placebo-controlled designs.","Altimmune expects to begin the AUD trial in Q2 2025 and the ALD trial in Q3 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001326190-25-000024","json":"https://secwatch.observer/filing/0001326190-25-000024.json","markdown":"https://secwatch.observer/filing/0001326190-25-000024.md","text":"https://secwatch.observer/filing/0001326190-25-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000132619025000024/0001326190-25-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000132619025000024/alt-20250313x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T20:31:30.649636+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}